Pharma major

制药巨头

Lupin Ltd

鲁宾有限公司

on Friday said it has launched

周五表示已推出

Ipratropium Bromide nasal spray

异丙托溴铵鼻喷雾剂

, used in treatment of runny nose, in the US market.

，用于治疗流鼻涕，在美国市场。

The Ipratropium Bromide nasal solution (nasal spray) launched in the US is of strengths 0.03 per cent and 0.06 per cent,

美国上市的异丙托溴铵鼻喷雾剂（鼻喷剂）浓度为0.03%和0.06%，

Lupin Ltd

鲁宾有限公司

said in a regulatory filing.

在监管文件中表示。

Ipratropium Bromide nasal spray 0.03 per cent and 0.06 per cent are bioequivalent to Atrovent nasal spray in the same strengths of

0.03% 和 0.06% 的异丙托溴铵鼻喷雾剂与相同强度的 Atrovent 鼻喷雾剂具有生物等效性。

Boehringer Ingelheim Pharmaceuticals

勃林格殷格翰制药公司

, Inc, it added.

`, Inc.`，它补充道。

Lupin said Ipratropium Bromide nasal spray 0.03 per cent is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older.

鲁宾说，0.03%的异丙托溴铵鼻喷雾剂适用于6岁及以上成人和儿童因过敏性和非过敏性常年性鼻炎引起的流涕症状的缓解。

Ipratropium Bromide nasal spray 0.06 per cent is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal

0.06%异丙托溴铵鼻喷雾剂适用于缓解与普通感冒或季节性相关的流涕症状。

allergic rhinitis

过敏性鼻炎

for adults and children aged 5 years and older, it added.

它补充说，适用于5岁及以上的成人和儿童。

Live Events

现场活动

Citing IQVIA MAT May 2025 data, the company said Ipratropium Bromide nasal solution (Atrovent) had estimated annual sales of USD 63 million in the US. PTI

引用IQVIA MAT 2025年5月的数据，该公司表示，异丙托溴铵鼻喷雾剂（Atrovent）在美国的年销售额估计为6300万美元。PTI

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)